Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Leila J Jackson
School of Medicine,
Research 2 Room 5101, 12700 E. 19th Avenue Mail Stop B182, Aurora, Colorado 80045
Tanzania
Research Article
B Cell Receptor Recognition of Glatiramer Acetate is Required for Efficacy through Antigen Presentation and Cytokine Production
Author(s): Leila J Jackson, Sean Selva, Tracy Niedzielko and Timothy VollmerLeila J Jackson, Sean Selva, Tracy Niedzielko and Timothy Vollmer
Multiple Sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) leading to neuronal demyelination, lack of remyelination, and axonal loss. If left untreated, patients inevitably suffer from severe cognitive, psychological and physical disabilities. Although not yet approved, B cell depletion achieved with anti-CD20 monoclonal antibodies is the most effective therapy to-date in MS patients. As this therapeutic depletes immune cells potentially important in pathogen immunity, an immense need remains for highly efficacious therapeutics maintaining a favorable safety profile. Even amongst the emergence of new therapeutic options for patients with MS, the myelin basic protein mimetic, Copaxone (glatiramer acetate, GA), remains the most commonly prescribed drug in the United States. As specific B cell depletion appears to be the most effective therapy for MS p.. View More»
DOI:
10.4172/2155-9899.1000185